Actively Recruiting
Evaluation of Treatment Response of Colorectal Cancer Liver Metastases Using Intravoxel Incoherent Motion Diffusion Weighted Imaging
Led by M.D. Anderson Cancer Center · Updated on 2026-01-14
70
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the use of intravoxel incoherent motion diffusion weighted imaging (IVIM DWI), a new type of imaging scan, to measure treatment response in patients with colorectal cancer that has spread to the liver. The study aims to detect differences in diffusion-related imaging parameters before and after chemotherapy between patients who respond to treatment and those who do not. Additional goals include assessing changes in respiratory-triggered DWI and T2 maps and correlating imaging results with the amount of tumor necrosis seen in pathology after treatment. Participants will undergo IVIM DWI scans lasting about 10 minutes during their standard MRI within 30 days before starting chemotherapy and again after 4 to 6 cycles of preoperative chemotherapy. The chemotherapy regimens studied include combinations such as FOLFOX, FOLFIRI, or FOLFOXIRI, with or without biologic agents. The study does not involve randomization or blinding, focusing on imaging performed alongside usual care treatments. During the study, researchers will measure changes in the true diffusion coefficient and other imaging parameters over up to 5 months, corresponding to chemotherapy cycles. Patients will have scans before and after chemotherapy to evaluate treatment response. The study includes safety monitoring for allergic reactions to gadolinium contrast and other eligibility assessments. Total participation time depends on chemotherapy duration and follow-up at the study center.
CONDITIONS
Brief Title
An Investigational Scan (Intravoxel Incoherent Motion Diffusion Weighted Imaging) for the Evaluation of Colorectal Cancer Liver Metastases Treatment Response
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with treatment-naive resectable colorectal liver metastases starting chemotherapy with FOLFOX, FOLFIRI, or FOLFOXIRI, with or without biologic agents
- Presence of at least one colorectal liver metastasis measuring at least 1 cm
- Anticipated follow-up before and after surgery at the study center
You will not qualify if you...
- Prior preoperative chemotherapy for colorectal liver metastases
- Undergoing radiation therapy, ablative therapies, or other non-surgical liver-directed treatments
- Allergy to gadolinium contrast agents
- Presence of a pacemaker
- Weight greater than 400 pounds
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 months (duration of preoperative chemotherapy cycles)
Participants undergo intravoxel incoherent motion diffusion weighted imaging (IVIM DWI) during standard of care MRI to evaluate colorectal cancer liver metastases treatment response.
2 imaging visits: one within 30 days of starting chemotherapy and one after 4-6 cycles of chemotherapy
Trial Site Locations
Total: 1 location
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
P
Priya R Bhosale
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here